Readoutin 14d
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — AK105 Injection
Phase 3 primary completion: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC).
- Date
- Dec 2026
- Type
- Readout
- Indication
- Advanced Hepatocellular Carcinoma (HCC)